Palifermin for the reduction of acute GVHD: A randomized, double-blind, placebo-controlled trial

Bone Marrow Transplantation

Volumn 47, Issue 10, 2012, Pages 1350-1355

  Jagasia, M H ^a   Abonour, R ^b   Long, G D ^c   Bolwell, B J ^d   Laport, G G ^e   Shore, T B ^f   Durrant, S ^g   Szer, J ^h   Chen, M G ⁱ   Lizambri, R ⁱ   Waller, E K ^j  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

^b INDIANA UNIVERSITY   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

^e STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^f NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^g ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^h ROYAL MELBOURNE HOSPITAL   (Australia)

ⁱ AMGEN INC   (United States)

^j EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

GVHD; Hematopoietic cell transplantation; MTX; Palifermin

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETOPOSIDE; FLUDARABINE; MELPHALAN; METHOTREXATE; PALIFERMIN; PLACEBO; TACROLIMUS;

ABDOMINAL PAIN; ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ANOREXIA; ANXIETY; ARTICLE; ASTHENIA; BACKACHE; CONSTIPATION; CONTROLLED STUDY; COUGHING; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; DYSPNEA; ENGRAFTMENT; ERYTHEMA; EXPLORATORY RESEARCH; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL DISEASE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HLA MATCHING; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOMAGNESEMIA; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYELOABLATIVE CONDITIONING; NAUSEA; NEUTROPHIL COUNT; ORAL MUCOSITIS; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PLATELET ENGRAFTMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN DISEASE; TACHYCARDIA; TONGUE DISEASE; UNRELATED DONORS; VOMITING; WHOLE BODY RADIATION;

ACUTE DISEASE; ADOLESCENT; ADULT; DOUBLE-BLIND METHOD; FEMALE; FIBROBLAST GROWTH FACTOR 7; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; STEM CELL TRANSPLANTATION; STOMATITIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 84867402278     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2011.261     Document Type: Article

References (16)

1. Jenq RR, van den Brink MR. Allogeneic haematopoietic stem cell transplantation: individualized stem cell and immune therapy of cancer. Nat Rev Cancer 2010; 10: 213-221.
2. Jacobsohn DA, Vogelsang GB. Acute graft versus host disease. Orphanet J Rare Dis 2007; 2: 35.
3. Vera-Llonch M, Oster G, Ford CM, Lu J, Sonis S. Oral mucositis and outcomes of allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies. Support Care Cancer 2007; 15: 491-496.
4. Ram R, Gafter-Gvili A, Yeshurun M, Paul M, Raanani P, Shpilberg O. Prophylaxis regimens for GVHD: systematic review and meta-analysis. Bone Marrow Transplant 2009; 43: 643-653.
5. Cutler C, Li S, Kim HT, Laglenne P, Szeto KC, Hoffmeister L et al. Mucositis after allogeneic hematopoietic stem cell transplantation: a cohort study of methotrexate- and non-methotrexate-containing graft-versus-host disease prophylaxis regimens. Biol Blood Marrow Transplant 2005; 11: 383-388.
6. Krijanovski OI, Hill GR, Cooke KR, Teshima T, Crawford JM, Brinson YS et al. Keratinocyte growth factor separates graft-versus-leukemia effects from graft-versus-host disease. Blood 1999; 94: 825-831.
7. Panoskaltsis-Mortari A, Lacey DL, Vallera DA, Blazar BR. Keratinocyte growth factor administered before conditioning ameliorates graft-versus-host disease after allogeneic bone marrow transplantation in mice. Blood 1998; 92: 3960-3967.
8. Panoskaltsis-Mortari A, Taylor PA, Rubin JS, Uren A, Welniak LA, Murphy WJ et al. Keratinocyte growth factor facilitates alloengraftment and ameliorates graftversus- host disease in mice by a mechanism independent of repair of conditioning-induced tissue injury. Blood 2000; 96: 4350-4356.
9. Spielberger R, Stiff P, Bensinger W, Gentile T, Weisdorf D, Kewalramani T et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 2004; 351: 2590-2598.
10. Nasilowska-Adamska B, Rzepecki P, Manko J, Czyz A, Markiewicz M, Federowicz I et al. The influence of palifermin (Kepivance) on oral mucositis and acute graft versus host disease in patients with hematological diseases undergoing hematopoietic stem cell transplant. Bone Marrow Transplant 2007; 40: 983-988.
11. Langner S, Staber P, Schub N, Gramatzki M, Grothe W, Behre G et al. Palifermin reduces incidence and severity of oral mucositis in allogeneic stem-cell transplant recipients. Bone Marrow Transplant 2008; 42: 275-279.
12. Blazar BR, Weisdorf DJ, Defor T, Goldman A, Braun T, Silver S et al. Phase 1/2 randomized, placebo-control trial of palifermin to prevent graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT). Blood 2006; 108: 3216-3222.
13. Levine JE, Blazar BR, DeFor T, Ferrara JL, Weisdorf DJ. Long-term follow-up of a phase I/II randomized, placebo-controlled trial of palifermin to prevent graftversus- host disease (GVHD) after related donor allogeneic hematopoietic cell transplantation (HCT). Biol Blood Marrow Transplant 2008; 14: 1017-1021.
14. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15: 825-828.
15. World Health Organization. A Handbook for Reporting Results of Cancer Treatment. World Health Organization: Geneva, 1979.
16. Stiff PJ, Emmanouilides C, Bensinger WI, Gentile T, Blazar B, Shea TC et al. Palifermin reduces patient-reported mouth and throat soreness and improves patient functioning in the hematopoietic stem-cell transplantation setting. J Clin Oncol 2006; 24: 5186-5193.